Filtered By:
Therapy: Chemotherapy
This page shows you your search results in order of date. This is page number 3.
Order by Relevance | Date
Total 70189 results found since Jan 2013.
Clinical outcomes of ramucirumab plus docetaxel in the treatment of patients with non-small cell lung cancer after immunotherapy: a systematic literature review
CONCLUSIONS: Cumulatively, these results support the combination of ramucirumab plus docetaxel as an effective and safe subsequent therapy for the treatment of patients with metastatic NSCLC with disease progression irrespective of previous ICI treatment.PMID:37731641 | PMC:PMC10507469 | DOI:10.3389/fonc.2023.1247879
Source: Cancer Control - September 21, 2023 Category: Cancer & Oncology Authors: Edward B Garon Carla Visseren-Grul Maria Teresa Rizzo Tarun Puri Suresh Chenji Martin Reck Source Type: research
Effectiveness and safety of Shenqi Fuzheng injection combined with platinum-based chemotherapy for treatment of advanced non-small cell lung cancer: a systematic review and meta-analysis
CONCLUSION: SFI combined with PBC for the treatment of advanced NSCLC improved the ORR, DCR, and quality of life, and reduced the incidence of myelosuppression and gastrointestinal adverse reactions. However, considering the limitations of existing evidence, further verification using high-quality RCTs is required.SYSTEMATIC REVIEW REGISTRATION: https://inplasy.com/inplasy-2022-7-0026, identifier INPLASY202270026.PMID:37731634 | PMC:PMC10507621 | DOI:10.3389/fonc.2023.1198768
Source: Cancer Control - September 21, 2023 Category: Cancer & Oncology Authors: Chenxi Qiao Shuaihang Hu Dandan Wang Kangdi Cao Zhuo Wang Xinyan Wang Xiumei Ma Zheng Li Wei Hou Source Type: research
Serum basic fibroblast growth factor and interleukin-1 β predict the effect of first-line chemotherapy in patients with advanced gastric cancer
CONCLUSION: The FLOT regimen was effective in reducing the serum CEA, CA199, and TPS levels as well as in improving the 1-year survival rate of patients with good tolerability, making it worthy of clinical promotion and application.PMID:37731570 | PMC:PMC10507556 | DOI:10.12998/wjcc.v11.i26.6083
Source: Cancer Control - September 21, 2023 Category: Cancer & Oncology Authors: Li Zheng Li-Hong Gan Ling Yao Bin Li Ya-Qin Huang Fu-Bao Zhang Meng-Qi Kuang Nian Fang Source Type: research
A randomized trial to evaluate the preventive effect of lafutidine on chemotherapy-induced peripheral neuropathy in patients treated with carboplatin and paclitaxel for lung cancer
CONCLUSIONS: Although the preventive effect of lafutidine on CIPN could not be demonstrated statistically, lafutidine FACT/GOG-Ntx scores showed a trend toward decreased neurotoxicity as chemotherapy proceeded. More reliable studies using lafutidine on the prevention of CIPN should be conducted.TRIAL REGISTRATION: Japan Registry of Clinical Trials identifier: jRCTs021200031.PMID:37731302 | DOI:10.21037/apm-23-90
Source: Cancer Control - September 21, 2023 Category: Cancer & Oncology Authors: Katsuya Cho Hirotaka Saikawa Tatsuya Hashimoto Hiroshi Katagiri Yoshihiro Owada Kazuhiro Yakuwa Itaru Fujimura Yu Utsumi Masachika Akiyama Hiromi Nagashima Fumiaki Takahashi Makoto Maemondo Source Type: research
Patterns of PET-positive residual tissue at interim restaging and risk of treatment failure in advanced-stage Hodgkin's lymphoma: an analysis of the randomized phase III HD18 trial by the German Hodgkin Study Group
CONCLUSION: PET-2-positive residuals of AS-HL are mostly located in the mediastinum, and a majority of patients have few affected regions. The risk of progression was twofold higher in patients with more than two positive regions in PET-2.PMID:37735258 | DOI:10.1007/s00259-023-06431-w
Source: Molecular Medicine - September 21, 2023 Category: Molecular Biology Authors: Justin Ferdinandus Lutz van Heek Katrin Roth Markus Dietlein Hans-Theodor Eich Christian Baues Peter Borchmann Carsten Kobe Source Type: research
Long non-coding RNAs in non-small cell lung cancer: Implications for preventing therapeutic resistance
Biochim Biophys Acta Rev Cancer. 2023 Sep 19:188982. doi: 10.1016/j.bbcan.2023.188982. Online ahead of print.ABSTRACTLung cancer has the highest mortality and morbidity rates among all cancers worldwide. Despite many complex treatment options, including radiotherapy, chemotherapy, targeted drugs, immunotherapy, and combinations of these treatments, efficacy is low in cases of resistance to therapy, metastasis, and advanced disease, contributing to low overall survival. There is a pressing need for the discovery of novel biomarkers and therapeutic targets for the early diagnosis of lung cancer and to determine the efficacy ...
Source: Biochimica et Biophysica Acta - September 21, 2023 Category: Biochemistry Authors: Wenjuan Liu Bingli Zuo Wenting Liu Yanfei Huo Nasha Zhang Ming Yang Source Type: research
Dabrafenib and trametinib in Langerhans cell histiocytosis and other histiocytic disorders
Haematologica. 2023 Sep 21. doi: 10.3324/haematol.2023.283295. Online ahead of print.ABSTRACTStandard treatment for Langerhans Cell Histiocytosis (LCH) is chemotherapy, with high failure rates. Since MAP-kinase activating mutations are found in most cases, BRAF- and MEKinhibitors have been used successfully to treat patients with refractory or relapsed disease. However, data on long-term responses in children are limited and no data exist on their use as first-line therapy. We treated thirty-four patients (26 LCH, 2 Juvenile Xanthogranuloma, 2 Rosai-Dorfman Disease, 4 presumed single site-CNS histiocytosis) with either dab...
Source: Haematologica - September 21, 2023 Category: Hematology Authors: Eily Cournoyer Justin Ferrell Susan Sharp Anish Ray Michael Jordan Christopher Dandoy Michael Grimley Somak Roy Robert Lorsbach Arnold C Merrow Adam Nelson Allison Bartlett Jennifer Picarsic Ashish Kumar Source Type: research
Immune checkpoint molecule DNAM-1/CD112 axis is a novel target for NK-cell therapy in acute myeloid leukemia
In conclusion, the modification of the DNAM-1/CD112 axis in NK cells may be an effective novel immunotherapy for AML. Furthermore, these results suggest the potential of the expression levels of these molecules as prognostic markers in AML.PMID:37731380 | DOI:10.3324/haematol.2023.282915
Source: Haematologica - September 21, 2023 Category: Hematology Authors: Yuta Kaito Emi Sugimoto Fumi Nakamura Yutaka Tsukune Makoto Sasaki Shunsuke Yui Hiroki Yamaguchi Susumu Goyama Yasuhito Nannya Kinuko Mitani Hideto Tamura Yoichi Imai Source Type: research
Site-specific delivery of cisplatin and paclitaxel mediated by liposomes: A promising approach in cancer chemotherapy
Environ Res. 2023 Sep 19:117111. doi: 10.1016/j.envres.2023.117111. Online ahead of print.ABSTRACTThe site-specific delivery of drugs, especially anti-cancer drugs has been an interesting field for researchers and the reason is low accumulation of cytotoxic drugs in cancer cells. Although combination cancer therapy has been beneficial in providing cancer drug sensitivity, targeted delivery of drugs appears to be more efficient. One of the safe, biocompatible and efficient nano-scale delivery systems in anti-cancer drug delivery is liposomes. Their particle size is small and they have other properties such as adjustable phy...
Source: Environmental Research - September 21, 2023 Category: Environmental Health Authors: Jianyong Zou Source Type: research
Prevention and management of hepatitis B virus reactivation in patients with hematological malignancies in the targeted therapy era
World J Gastroenterol. 2023 Sep 7;29(33):4942-4961. doi: 10.3748/wjg.v29.i33.4942.ABSTRACTHepatitis due to hepatitis B virus (HBV) reactivation can be serious and potentially fatal, but is preventable. HBV reactivation is most commonly reported in patients receiving chemotherapy, especially rituximab-containing therapy for hematological malignancies and those receiving stem cell transplantation. Patients with inactive and even resolved HBV infection still have persistence of HBV genomes in the liver. The expression of these silent genomes is controlled by the immune system. Suppression or ablation of immune cells, most imp...
Source: World Journal of Gastroenterology : WJG - September 21, 2023 Category: Gastroenterology Authors: Joyce Wing Yan Mak Alvin Wing Hin Law Kimmy Wan Tung Law Rita Ho Carmen Ka Man Cheung Man Fai Law Source Type: research
Oestrogen receptor-independent actions of oestrogen in cancer
Mol Biol Rep. 2023 Sep 20. doi: 10.1007/s11033-023-08793-8. Online ahead of print.ABSTRACTOestrogen, the primary female sex hormone, plays a significant role in tumourigenesis. The major pathway for oestrogen is via binding to its receptor [oestrogen receptor (ERα or β)], followed by nuclear translocation and transcriptional regulation of target genes. Almost 70% of breast tumours are ER + , and endocrine therapies with selective ER modulators (tamoxifen) have been successfully applied. As many as 25% of tamoxifen-treated patients experience disease relapse within 5 years upon completion of chemotherapy. In such cases, t...
Source: Molecular Biology Reports - September 21, 2023 Category: Molecular Biology Authors: Prarthana Gopinath Revathi Paramasivam Oviya Gopal Gopisetty Source Type: research
Research Progress in Immunotherapy of Gliomas
J Integr Neurosci. 2023 Aug 14;22(5):118. doi: 10.31083/j.jin2205118.ABSTRACTAlthough some progress has been made in tumor treatment, gliomas remain one of the tumors that can still seriously threaten human life and health. Due to the particularity of the immune microenvironment of the central nervous system and the strong invasiveness of tumors, the treatment of gliomas remains a major challenge. Currently, researchers have explored a large number of immunotherapy programs to improve the survival and prognosis of glioma patients, including tumor vaccines, immune checkpoint inhibitors, adoptive cell transfer therapy, viral...
Source: Journal of Integrative Neuroscience - September 21, 2023 Category: Neuroscience Authors: Zhi-Hong Duan Zi-Long Wei Source Type: research
Differential benefit of metronomic chemotherapy among triple negative breast cancer subtypes treated in the IBCSG Trial 22-00
CONCLUSIONS: Our results show a differential benefit of low-dose CM therapy across different TNBC subtypes. Low-dose CM therapy could be considered as a potential immunomodulatory strategy for TNBC tumors with IM subtype in the early-disease setting.PMID:37733800 | DOI:10.1158/1078-0432.CCR-23-1267
Source: Cell Research - September 21, 2023 Category: Cytology Authors: Andrea Joaquin Garcia Mattia Rediti David Venet Samira Majjaj Roswitha Kammler Elisabetta Munzone Lorenzo Gianni Beat Th ürlimann Istv án Láng Marco Colleoni Sherene Loi Giuseppe Viale Meredith M Regan Laurence Buisseret Fran çoise Rothé Christos Sot Source Type: research
ATM mutations associate with distinct co-mutational patterns and therapeutic vulnerabilities in NSCLC
CONCLUSIONS: ATM mutations define a distinct subset of NSCLC associated with KRAS mutations, increased TMB, decreased TP53 and EGFR co-occurrence, and potential increased sensitivity to ICIs in the context of DNA-damaging chemotherapy.PMID:37733794 | DOI:10.1158/1078-0432.CCR-23-1122
Source: Cell Research - September 21, 2023 Category: Cytology Authors: Natalie I Vokes Ana Galan Cobo Margarita Fernandez-Chas David Molkentine Santiago Trevi ño Vitaly Druker Yu Qian Sonia Patel Stephanie Schmidt Lingzhi Hong Jeff Lewis Waree Rinsurongkawong Vadeerat Rinsurongkawong J Jack Lee Marcelo V Negrao Don L Gibbon Source Type: research
Prevention and management of hepatitis B virus reactivation in patients with hematological malignancies in the targeted therapy era
World J Gastroenterol. 2023 Sep 7;29(33):4942-4961. doi: 10.3748/wjg.v29.i33.4942.ABSTRACTHepatitis due to hepatitis B virus (HBV) reactivation can be serious and potentially fatal, but is preventable. HBV reactivation is most commonly reported in patients receiving chemotherapy, especially rituximab-containing therapy for hematological malignancies and those receiving stem cell transplantation. Patients with inactive and even resolved HBV infection still have persistence of HBV genomes in the liver. The expression of these silent genomes is controlled by the immune system. Suppression or ablation of immune cells, most imp...
Source: World Journal of Gastroenterology - September 21, 2023 Category: Gastroenterology Authors: Joyce Wing Yan Mak Alvin Wing Hin Law Kimmy Wan Tung Law Rita Ho Carmen Ka Man Cheung Man Fai Law Source Type: research
